BGM Group Ltd. (BGM) Stock Price & Analysis
BGM Group Ltd. (BGM) closed at USD 8.59 on Thursday, October 15, 2026, down 10.05% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 9.55; the Oct 15, 2026 session ranged USD 8.59–8.59 on volume of 617 shares. Market capitalization is $114.71M, with a 52-week range of USD 6.45–303 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BGM.md
Key facts (BGM)
- Analysts: None.
- Total return with dividends: 1Y -97.0% vs S&P 500 +18.1%; 5Y -98.5% vs S&P 500 +85.1%.
Analysts (BGM)
Consensus None.
Total return (dividends reinvested) (BGM)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -97.0% | -98.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -97.0% | -56.8% |
| Volatility (annualized) | 130.0% | 94.7% |
| Max drawdown | -97.6% (Nov 2025→Sep 2026) | -98.8% (Oct 2021→Sep 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 8.59 |
|---|---|
| Change | ▼ 10.05% (down) |
| Previous Close | USD 9.55 |
| Open | USD 8.59 |
| Day Range | USD 8.59 – 8.59 |
| 52-Week Range | USD 6.45 – 303 |
| Volume | 617 shares |
| Market Cap | $114.71M |
| Exchange | NCM |
Technical Analysis (BGM)
Nexqual's technical model rates BGM "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 44.64 (neutral) |
| vs SMA50 | Above (USD 8.47) |
| MACD | 0.44 (positive) |
Analyst Ratings (BGM)
Wall Street analysts rate BGM "None", per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | None |
|---|
Earnings (BGM)
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (BGM)
| Total Revenue | $47.90M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +69.80% |
| Gross Margin | +16.93% |
| Operating Margin | -3.61% |
| Profit Margin | -44.22% |
| ROE | -7.41% |
| Debt / Equity | 0 |
| Current Ratio | 1.25 |
| Total Cash | $11.55M |
| Total Debt | $1.18M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (BGM)
Nexqual rates BGM Group Ltd.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Strong — Revenue +70% YoY (latest Q) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $12M cash vs $1M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $3M (TTM) |
| Efficiency | Critical — ROE -7%, ROA -2.2% |
Ownership (BGM)
| Insider Ownership | +38.05% |
|---|---|
| Institutional Ownership | +0.10% |
| Shares Outstanding | 12.69M |
| Float | 4.59M |
| Short % of Float | +0.04% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (BGM)
BGM Group Ltd. is led by Huandi Zhao (age 40), Co-Chief Executive Officer & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| Co-Chief Executive Officer & Director | Huandi Zhao (age 40) |
|---|---|
| Chief Financial Officer | Yaxuan Zhai (age 30) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt